At this year’s Bioprocessing Summit, Dr Graham Whyteside presented on 'Inducible synthetic promoters for the production of gene therapy viral vectors'. Synpromics has developed a novel proprietary inducible expression platform that provides exquisite and tuneable control of gene expression, far surpassing the control afforded by current inducible systems. These inducible promoters complement the existing extensive range of constitutive promoters designed by Synpromics that can allow tailored gene expression to a desired level.

Opinion at the conference on the state of the field was divided. Many were excited by the new technologies and opportunities around bioprocessing, fuelled by the newly released and well-annotated genome for CHO cells (Horizon) and the possibilities that this afforded in targeted integration strategies. Others, however, voiced frustration and scepticism about whether the FDA would approve these technologies and modified strains.

Despite this division, Synpromics’ inducible promoters were met with universally positive feedback both from academics and pharma companies. Many were impressed by the inducible technology due to its excellent control, exceeding currently available systems. Indeed, many asked how they could “get their hands on our promoters?” as they have so many applications.

The novel inducible systems have a myriad of potential uses. Their exquisite control makes them ideal for use in bioprocessing thanks to their tuneability and the identification of multiple inducers. This would allow unprecedented control of gene expression so that users boost or subdue expression levels. In addition, the novel inducible system has applications in therapeutics as it could be used in gene or CAR-T therapy as a switch to either activate a therapeutic gene or as a kill-switch, enabling an extra layer of safety.​

This latest innovation adds to Synpromics multi-faceted portfolio of technologies, and is invaluable to the company’s development, potentially solving many of the major problems encountered in the fields of bioprocessing and gene therapy.​

 Download the poster upon which Dr Whyteside’s presentation was based.​​​